ADAR1 Capital Management »

Kymera Therapeutics shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Kymera Therapeutics (KYMR) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Kymera Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Kymera Therapeutics held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Kymera Therapeutics by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $643k 16k 40.20

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Roivant Sciences SHS (ROIV)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Protagonist Therapeutics (PTGX)
Cytokinetics Com New (CYTK)
Keros Therapeutics (KROS)
Royalty Pharma Shs Class A (RPRX)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New (MACK)
Ascendis Pharma A/s Sponsored Adr (ASND)
Arbutus Biopharma (ABUS)
Avrobio Ord (AVRO)
Beigene Sponsored Adr (BGNE)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)

View all positions for ADAR1 Capital Management

Top funds holding Kymera Therapeutics

T. Rowe Price Associates
Baker Bros. Advisors
Atlas Venture Life Science Advisors
BVF
Wellington Management Company
Vanguard Group
FMR
venBio Select Advisor
BlackRock
Artal Group
Redmile Group
Rock Springs Capital Management
Geode Capital Management
Marshall Wace
Morgan Stanley

View all funds holding Kymera Therapeutics